Gate2Brain
  • Home
  • Company
  • Team
  • Technology
  • Pipeline-Proof of Concept
  • Investors
  • News & Media
  • Contact
  • Menu Menu

Gate2Brain co-signs its first article in ACS Publications under the title “Amphiphilic Polymeric Nanoparticles Modified with Protease-Resistant Peptide Shuttle for the Delivery of SN-38 in Diffuse Intrinsic Pontine Glioma”

Publications
Gate2Brain

Alexandra Bukchin, Macarena Sanchez-Navarro, Adam Carrera, Claudia Resa-Pares, Helena Castillo-Ecija, Leire Balaguer-Lluna, Meritxell Teixidó, Nagore G. Olaciregui, Ernest Giralt, Angel M. Carcaboso, Alejandro Sosnik

Abstract

Diffuse intrinsic pontine glioma (DIPG) is a chemo-resistant, incurable pediatric tumor of the central nervous system (CNS). The blood–brain barrier (BBB) remains intact in the course of the disease, preventing drugs from entering the brain and resulting in therapeutic failure. The topoisomerase I inhibitor SN-38 shows strong anticancer activity in a patient-derived DIPG cell line in vitro, though a low CNS bioavailability and anti-DIPG efficacy in vivo. In this work, we produced SN-38-loaded

polymeric nanoparticles of an amphiphilic chitosan (CS)-g-poly (methyl methacrylate)-poly (acrylic acid) copolymer that were surface-modified with a peptide shuttle that improves transport across the BBB. Drug-loaded nanoparticles displayed a size of ∼200 nm (intensity distribution) and a potential of +16 mV. The cytocompatibility and endocytosis assayed in DIPG cells (both attached and in suspension) indicated that the nanoparticles are compatible and mainly internalized by clathrin-mediated endocytosis and that the anticancer activity of SN-38 is preserved after nanoencapsulation. In addition, a tandem permeability/anticancer activity study utilizing a coculture model of BBB endothelial cells and DIPG cell spheroids demonstrated that the modified nanoparticles cross a BBB endothelial cell monolayer to a higher extent than the unmodified counterparts and are taken up by DIPG cells. After 72 h of exposure, both SN-38-loaded nanoparticles killed ∼84-88% of the DIPG cells in suspension, indicating that they reach a concentration above the inhibitory concentration 50 of the drug. Finally, the brain accumulation of the drug-loaded nanoparticles upon intravenous injection to Hsd:ICR mice was preliminarily characterized by light sheet fluorescence microscopy. As opposed to unmodified SN-38-loaded nanoparticles, the modified counterparts bind the brain blood vessels and accumulate in the cerebral parenchyma to a large extent.

These results confirm the potential of this nanotechnology platform to deliver anticancer agents to the brain in DIPG and other brain tumors with fully conserved BBB.

 


Source:
ACS Publications
https://pubs.acs.org/doi/pdf/10.1021/acsanm.0c02888

January 14, 2021/by Susana Meneses
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on LinkedIn
  • Share by Mail
https://gate2brain.com/wp-content/uploads/2021/01/News.jpg 648 1329 Susana Meneses https://gate2brain.com/wp-content/uploads/2020/12/Logo-Gate1Brain500pxGrueso.png Susana Meneses2021-01-14 15:22:392021-05-20 13:19:21Gate2Brain co-signs its first article in ACS Publications under the title “Amphiphilic Polymeric Nanoparticles Modified with Protease-Resistant Peptide Shuttle for the Delivery of SN-38 in Diffuse Intrinsic Pontine Glioma”

CATEGORIES

  • Clipping
  • Events
  • News
  • Podcast
  • Press releases
  • Publications
  • Videos

Events

  • 📢 On December 13h, Gate2Brain will be participating together with Maribel Berges (AFFIRMA BIOTECH SL), Sven Dr. Mulfinger (Dana_positive maternal health), and Diana Ballart (The Smart Lollipop) in the i4kids Closing Event 2022, sharing achievements and failures of entrepreneurs in #pediatric and maternal #healthcare.i4kidsi4kids Closing Event 2022December 7, 2022 - 12:37
  • WomenStartupAwards, in the "Inspiration" category.WomeninTechSpainFinalist of Women Startup AwardsNovember 15, 2022 - 17:46
  • GORDON CONFERENCESgate2brainGordon Research ConferencesNovember 3, 2022 - 11:41
  • Gate2Brain's retreat 2022Gate2BrainGate2Brain’s retreat 2022October 24, 2022 - 19:27
  • BIO EUROPE 2022GATE2BRAINGate2Brain at BIO-EUROPE 2022September 22, 2022 - 13:39

SOCIAL

  • linkedin
  • youtube

RSS RSS Ciencia

  • What will the d·Health Barcelona Part Time program clinical immersion be like? January 24, 2023 biocat
  • Good start to the year in investment and advances in projects at science facilities January 24, 2023 biocat
  • AseBio and Biocat present BIOSPAIN 2023 in Barcelona to over 200 people from the sector January 16, 2023 biocat
  • 2022: Healthcare research and innovation are strategic priorities for Catalonia December 23, 2022 biocat
  • 5th edition of CRAASH Barcelona program comes to an end December 21, 2022 biocat
  • Registration now open for presentation of 2022 BioRegion Report December 20, 2022 biocat
  • Open Innovation Forum consolidates role resolving innovation challenges in BioRegion December 20, 2022 biocat
  • AseBio and Biocat to present BIOSPAIN 2023 in Barcelona at public event open to whole ecosystem December 12, 2022 biocat
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social

  • linkedin
  • youtube
© Copyright –Edisenius
  • Privacy Policy
  • Legal Notice
  • Cookie Policy
BStartup of Banco de Sabadell invests in Gate2Brain biotech Gate2Brain Round Table in 100tífiques “Public Research and Research at Large Corpor...
Scroll to top
Manage Cookie Consent
This Website uses proprietary and third-party cookies to improve services and facilitate browsing. You can obtain further information about the cookies this site uses and how to limit them in the
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}